Search clinical trials for: Lapatinib-Placebo

Total 55172 results

Bristol-Myers Squibb

Completed

A Study of Dasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia

Myeloid Leukemia, Chronic

Japan
Merck Sharp & Dohme LLC

Terminated

A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)

Chronic Myelogenous Leukemia | Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Bristol-Myers Squibb

Completed

Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis

Scleroderma

United States
NeuromaxBionevia

Completed

12-Month Efficacy and Safety of Diepalrestat in Adults With Diabetic Peripheral Neuropathy, a DB, Placebo-Controlled Study (DE-DPN)

Diabetic Peripheral Neuropathy

Russian Federation
West German Study Group
GlaxoSmithKline

Terminated

Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer

Carcinoma, Ductal, Breast

Germany
National Cancer Institute (NCI)

Terminated

Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery

HER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIC Breast Cancer | Adenocarcinoma of the Gastroesophageal Junction | Recurrent Breast Cancer | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Recurrent Esophageal Cancer | Stage IV Esophageal Cancer | Stage IIIC Gastric... and other conditions

United States
Gary Schwartz
University of Colorado, Denver; North Shore University Hospital

Terminated

Lapatinib in Metastatic Breast Cancer Resistant to Hormone Therapy

Metastatic Breast Cancer

United States
Novartis

Completed

Drug Use Investigation for TYKERB Tablet (All Case Investigation)

Cancer
Boehringer Ingelheim

Completed

Nintedanib in Volunteers With Hepatic Impairment Compared With Healthy Volunteers

Hepatic Insufficiency

Germany
Huashan Hospital

Completed

Meropenem Penetration Across BBB in Patients With CNS Infection and Optimization of Meropenem Treatment

Central Nervous System Infections
Shanghai Chest Hospital

Not yet recruiting

To Evaluate the Efficacy of Afatinib in the Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer With NRG1 Fusion

NRG1-fused Non-small Cell Lung Cancer

China
Boehringer Ingelheim

Completed

LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy

Carcinoma, Non-Small-Cell Lung

United States, Spain, Taiwan, China, United Kingdom, Denmark, Canada, Korea, Republic of, Germany, Italy, Netherlands, Singapore, Austria, France, Portugal, Greece, India, Mexico, Hungary, Turkey, Argentina, Chile, Ireland
Zhou Chengzhi
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Recruiting

Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLC

Extensive Stage Small Cell Lung Cancer

China
Elevar Therapeutics

Terminated

A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC)

Metastatic Colorectal Cancer

United States
The First Affiliated Hospital of Xiamen University

Unknown

Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric Cancer

Locally Advanced or Metastatic Gastric Adenocarcinoma

China
Zhejiang Cancer Hospital

Recruiting

Toripalimab Combined With Apatinib Mesylate for the Treatment of Gastric Adenocarcinoma in a Prospective Randomized Multicenter Phase II Clinical Study

Gastric Adenocarcinoma

China
Hebei Medical University Fourth Hospital

Not yet recruiting

A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma
Hebei Medical University

Not yet recruiting

A Study of HIPEC Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells

Gastric Cancer
Renmin Hospital of Wuhan University

Completed

First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GC (RENMIN-213)

Advanced Gastric Adenocarcinoma

China
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate

Leukemia

United States
Boehringer Ingelheim

Completed

Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-positive Lung Adenocarcinoma

Non-squamous, Non-Small Cell Lung Cancer

Japan
Boehringer Ingelheim

No longer available

Afatinib (GILOTRIF®) in Patients Suffering From Tumors Harboring Neuregulin 1 (NRG1) Gene Alterations (Specifically NRG1 Gene Fusion-positive Advanced Solid Tumors)

Solid Tumors
University College, London
Boehringer Ingelheim

Completed

Efficacy and Safety Study of Afatinib to Treat Lung Cancer Patients (TIMELY)

Carcinoma, Non-Small-Cell Lung

United Kingdom
Boehringer Ingelheim

Completed

A Phase II Trial of Afatinib(BIBW 2992) in Third-line Treatment for Patients With Stage IIIB/IV Adenocarcinoma of the Lung Harbouring Wild-type Epidermal Growth Factor Receptor[EGFR]

Carcinoma, Non-Small-Cell Lung

Korea, Republic of
Boehringer Ingelheim

Terminated

Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.

Neoplasms

United States, Taiwan
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC

Small-cell Lung Cancer
The First Affiliated Hospital of Zhengzhou University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

The Phase II Trial of SHR-1210 Combined With Preoperative Chemotherapy or Apatinib for Locally Advanced ESCC

Locally Advanced Esophageal Squamous Cell Carcinoma

China
Pfizer

Completed

An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.

Lymphoma, Mantle-Cell

United States
The Netherlands Cancer Institute
GlaxoSmithKline

Unknown

Lapatinib Plus Trametinib in KRAS Mutant NSCLC (M14LTK)

Colorectal Cancer

Netherlands
M.D. Anderson Cancer Center
Bristol-Myers Squibb

Completed

Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Polycythemia Vera | Myelofibrosis | Leukemia, Myelomonocytic, Chronic | Hypereosinophilic Syndrome | Mastocytosis | Agnogenic Myeloid Metaplasia

United States
EDDC (Experimental Drug Development Centre), A*STAR...
Chiltern International Inc.

Withdrawn

Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies

Ph+ Acute Lymphoblastic Leukemia (Ph+ALL) | Ph- Acute Lymphoblastic Leukemia (Ph-ALL) | Chronic Myeloid Leukemia Accelerated Phase (CML-AP, Ph+) | Chronic Myeloid Leukemia Blast Crisis (CML-BC, Ph+)

United States, Singapore
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC

Chemotherapy Effect | BCLC Stage C Hepatocellular Carcinoma

China
Beijing 302 Hospital

Not yet recruiting

Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis

HER2-negative Breast Cancer Brain Metastases

China
Boehringer Ingelheim

Completed

Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

Korea, Republic of, Taiwan, Singapore, Japan
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia

Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia

United States
Sun Yat-sen University

Completed

Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer

Ovarian Cancer

China
Yongchang Zhang

Completed

Apatinib Combined With Vinorelbine for Non-driver Gene Mutation Non-small Cell Lung Cancer

Advanced Non Small Cell Lung Cancer

China
Huazhong University of Science and Technology

Unknown

PD-1 Monoclonal Antibody Plus Apatinib Combined With SBRT in HCC With PVTT

HCC

China
Hebei Medical University

Unknown

A Study of Intraperitoneal and Intravenous Paclitaxel Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells

Gastric Cancer With Positive Exfoliative Cancer Cells
Bristol-Myers Squibb

Completed

Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer

Breast Cancer

Czech Republic, United States, Spain, United Kingdom, Ireland, Poland, France, Sweden
Novartis Pharmaceuticals

Completed

Long-term Safety, Tolerability and Efficacy of Omalizumab in Japanese Children

Allergic Asthma

Japan
Duke University
Bristol-Myers Squibb; Genentech, Inc.

Completed

Ph I Dasatinib + Erlotinib in Recurrent MG

Glioblastoma | Gliosarcoma

United States
Peking University

Recruiting

Apatinib With Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma Of The Stomach

Gastric Cancer

China
Fuzhou General Hospital

Unknown

Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer.

Small Cell Lung Cancer | Lung Neoplasm | PD-1 Inhibitors

China
Chinese PLA General Hospital

Unknown

A Study of Apatinib in Combination With Raltitrexed Treatment in Patients With Advanced Colorectal Cancer

Colorectal Cancer

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)

Head and Neck Squamous Cell Carcinomas

China
Cedars-Sinai Medical Center

Completed

Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy

Pituitary Adenomas | Prolactinomas

United States
National Cancer Institute (NCI)

Terminated

Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery

Advanced Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma

United States
National Cancer Institute (NCI)

Completed

Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia

Squamous Cell Carcinoma of the Skin | Recurrent Skin Cancer | Stage 0 Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia

United States
Bristol-Myers Squibb

Completed

Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer

Breast Cancer | Metastasis

United States, Spain, Belgium, Peru, Italy, Argentina, France

Search clinical trials for: Lapatinib-Placebo

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Moldova

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations